



# Annual General Meeting

May 2023

IMRICOR MEDICAL SYSTEMS, INC (ASX:IMR)

[WWW.IMRICOR.COM](http://WWW.IMRICOR.COM)

# Disclaimer

The material contained in this presentation is intended to be general background information on Imricor Medical Systems, Inc. (**Imricor**) and its activities.

The information is supplied in summary form and is therefore not necessarily complete. It is not intended that it be relied upon as advice to investors or potential investors, who should consider seeking independent professional advice depending upon their specific investment objectives, financial situation or particular needs. The material contained in this presentation may include information derived from publicly available sources that have not been independently verified. None of Imricor, its officers, directors, employees and agents, nor any other person makes any representation or warranty as to the accuracy, completeness or reliability of the information contained in this presentation and none of them accepts responsibility or liability for any errors or omissions in this presentation whatsoever.

Unless otherwise noted, financial information in this presentation has been prepared in accordance with accounting principles generally accepted in the U.S. (**US GAAP**) and are denominated in US dollars.

This presentation may contain statements that constitute “forward-looking statements”. Forward-looking statements are statements about matters that are not historical facts. Forward-looking statements appear in a number of places in this presentation and include statements regarding Imricor’s intent, belief or current expectations with respect to its business and operations, market conditions, results of operations and financial condition.

Imricor uses words such as ‘will’, ‘may’, ‘expect’, ‘intend’, ‘seek’, ‘would’, ‘should’, ‘could’, ‘continue’, ‘plan’, ‘estimate’, ‘anticipate’, ‘believe’, ‘probability’, ‘risk’, ‘aim’, or other similar words to identify forward-looking statements. These forward-looking statements reflect Imricor’s current views with respect to future events and are subject to change, certain risks, uncertainties and assumptions which are, in many instances, beyond its control, and have been made based upon management’s expectations and beliefs concerning future developments and their potential effect upon Imricor. There can be no assurance that future developments will be in accordance with Imricor’s expectations or that the effect of future developments on Imricor will be those anticipated. Actual results could differ materially from

those which we expect, depending on the outcome of various factors. Investors and others are cautioned not to place undue reliance on forward-looking statements, particularly in light of the current economic climate and significant volatility, uncertainty and disruption caused by the COVID-19 pandemic.

Imricor is under no obligation to update any forward-looking statements contained in this presentation, whether as a result of new information, future events or otherwise, after the date of this presentation.

Imricor’s CHES Depositary Interests (**CDIs**) are traded on ASX in reliance on the safe harbour provisions of Regulation S under the US Securities Act of 1933, as amended, and in accordance with the procedures established pursuant to the provisions of a no-action letter dated 7 January 2000 given to ASX by the staff at the US Securities and Exchange Commission. The relief was given subject to certain procedures and conditions described in the no-action letter. One of the conditions is that the issuer provides notification of the Regulation S status of its securities in communications such as this presentation.

The distribution of this document outside of Australia may be restricted by law and any such restrictions should be observed. This presentation does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in the United States or in any other jurisdiction.



# Imricor's Board of Directors and CFO



**Steve Wedan**  
Executive Chair,  
President, & CEO

**Mark Tibbles**  
Deputy Chair,  
Non-Executive Director

**Anita Messal**  
Non-Executive Director

**Peter McGregor**  
Non-Executive Director

**Jonathon Gut**  
CFO



# Chair's Address





## ***Mission***

To establish a new standard of care for the \$US6bn<sup>1</sup> cardiac ablation market with real-time iCMR procedures.

**Number of iCMR Sites**

**Variety of Procedures**

**Breadth of Geographies**



1. Estimated based on data from United States, Europe, ANZ

# Key message

## Primary Drivers of Value

- **Expand indications** to complex procedures where iCMR adds the most value
  - Ventricular tachycardia (VT) and atrial fibrillation (Afib)
- **Expand geographies** where real-time iCMR ablations are approved and available
  - US, ANZ, Middle East, Asia

## Additional Drivers of Value

- Grow number of active iCMR sites
- Focus on new iCMR sites owned and controlled by cardiology
- Increase the number of procedures performed at each site
- Increased utilisation of MRI partners to drive the pipeline of iCMR labs



# 2022 Highlights

## Sites

- 9 active sites across Europe
- Contracted 3 new sites across Europe
- Expanded company's geographical footprint into Croatia and Italy
- Renewed sales focus on sites owned by Cardiology department

## Products

- Second generation ablation catheter submitted for approval in Europe
- First clinical evaluation of NorthStar-MR 3D Mapping System
- Diagnostic Catheter Technical Review Complete

## New Funding Secured

- Secured a US\$1.5 million loan under the North Dakota Commerce Department's Innovation Technology Loan Fund program
- US\$5 million convertible note deal
- A\$2.92m placement completed in the September quarter

## Partnerships

- Two agreements signed with Siemens
  - First agreement was an Access-I License Agreement
  - Second agreement was a Local Coil Agreement

## Trials

- Submitted for approval to commence VT ablation trial
- Trial named Vision-MR Ablation of VT or VISABL-VT
- Received first of two approvals from Leipzig Heart Centre Ethics Committee


## Other

- US restriction on CHES depository Interests removed
- Hosted virtual open house investor session
- Jonathon Gut promoted to CFO role



# NorthStar 3D Mapping System

Creating the central core of every iCMR practice by harnessing the value MRI brings



- System used successfully in human setting with **Siemens** MRI platform
- Development started in 2023 to interface with **GE HealthCare** MRI platform
- Working through the SIGNET consortium to interface with **Philips** MRI platform
- Same 3D mapping system experience no matter what kind of MRI system you have

We have shown you **can** do ablations in the iCMR.  
NorthStar will deliver the **why**.



NorthStar is not yet approved for sale



# Business Update and Outlook

---

# Clinical trials update

## Ventricular Tachycardia (VT) – VISABL-VT Trial (EU)

- Testing, and documentation completed for NorthStar to be added to the VISABL-VT study
- The Netherlands Central Committee on Research Involving Human Subjects (CCMO) has completed its review of the study protocol with positive results
- The Haga Hospital Ethics Committee reviewed it on 2 May
- Upon approval by the Haga Hospital Ethics Committee, the VISABL-VT trial can begin at that site.
- Enrollment to commence in Q3

## Atrial Flutter(AFL) – VISABL-AFL Trial (US)

- Received an approved Investigational Device Exemption (IDE) from the US Food and Drug Administration (FDA) to commence a global clinical trial to support FDA approval of Imricor's products in the US
- Following the IDE approval, four sites are confirmed for the VISABL-AFL study, and these sites are currently engaged in the activation process, which includes site contracting and site approval.
- Enrolment to commence in Q3



# Other FY2023 updates

- Twice as many procedures performed in Q1 2023 compared to Q4 2022
- Entered into a Master Services Agreement (MSA) with GE Healthcare in April, where GE Healthcare will pay Imricor to develop the hardware and software required to make NorthStar operate with the GE HealthCare MRI platform. The project to develop for the GE HealthCare MRI platform has begun
- Conducted our second “Real-time iCMR Ablation Global Summit” in Munich, Germany
- Participated in many medical and scientific congresses, such as annual meetings of:
  - The Society for Cardiovascular Magnetic Resonance (SCMR)
  - The European Heart Rhythm Association (EHRA) – *“Live in the Box” iCMR ablation presented*
  - The German Cardiology Society (DGK)
  - (next week) the Heart Rhythm Society (HRS)



# Path to significant scale



## Today



## Growing with new Indications



## Expanding Geographies



## Addressing Entire Market

### ***iCMR Atrial Flutter Ablations (AFL) in the EU***

- Establishing installed base of iCMR labs
- Building experience with iCMR environment and workflows
- Growing exposure with physician publications and presentations at summits and congresses
- These sites are set up for next step

### ***iCMR Ventricular Tachycardia Ablations (VT) in the EU***

- Key driver for adoption, with MRI adding significant value
- Higher ASP and higher reimbursement for VT ablations
- VISABL-VT clinical trial expected to begin in 2023, expected to catalyse market immediately

### ***FDA approval in US***

- Over 1100 sites
- Higher reimbursement compared to EU
- US revenue expected to be approximately 2x EU revenue
- IDE approval received
- VISABL-AFL clinical trial expected to begin in 2023

### ***Atrial Fibrillation Ablations (Afib) worldwide***

- Same consumable products used for VT
- Largest volume of procedures
- Access to full market potential of US\$6bn



# Our focus for the year ahead

## 1

### Commercialisation

- Activating sites
- Increasing procedure volumes across active sites
- Increased utilisation of MRI partners to drive the pipeline of iCMR labs
- Strong focus on labs owned by cardiologist department

## 2

### VISABL-VT Trial (EU)

- Commence trial
- Expected to catalyse market as value of VT is demonstrated

## 3

### VISABL-AFL Trial (US)

- Commence trial
- First major step into the significant US market for Imricor



# Contact Information

---

## Investors & Australian Media:

Simon Hinsley  
NWR Communications  
Email: [simon@nwrcommunications.com.au](mailto:simon@nwrcommunications.com.au)  
+61 401 809 653

## Investors:

Steve Wedan  
Executive Chair, President & CEO  
Email: [steve.wedan@imricor.com](mailto:steve.wedan@imricor.com)

## Rest of World Media:

Nick Twohy  
Vice President, Marketing and Business Development, Imricor  
Email: [nick.twohy@Imricor.com](mailto:nick.twohy@Imricor.com)

The Imricor logo features the word "imricor" in a dark blue, lowercase sans-serif font. The letter "o" is replaced by a stylized icon of a person's head and shoulders in white and yellow, set against a dark blue circular background.

imricor

---

FOLLOW US

